TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Sponsor: Conjupro Biotherapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 132 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT05948865 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05948865 Rescue Dossier →